Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6-7 Months of Age: A Phase 1/2 Randomized Trial

Background: Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract infections in infants. This phase 1/2, observer-blind, randomized, controlled study assessed the safety and immunogenicity of an investigational chimpanzee-derived adenoviral vector RSV vaccine (ChAd155-RSV, expressing RSV F, N, and M2-1) in infants.

Methods: Healthy 6- to 7-month-olds were 1:1:1-randomized to receive 1 low ChAd155-RSV dose (1.5 × 1010 viral particles) followed by placebo (RSV_1D); 2 high ChAd155-RSV doses (5 × 1010 viral particles) (RSV_2D); or active comparator vaccines/placebo (comparator) on days 1 and 31. Follow-up lasted approximately 2 years.

Results: Two hundred one infants were vaccinated (RSV_1D: 65; RSV_2D: 71; comparator: 65); 159 were RSV-seronaive at baseline. Most solicited and unsolicited adverse events after ChAd155-RSV occurred at similar or lower rates than after active comparators. In infants who developed RSV infection, there was no evidence of vaccine-associated enhanced respiratory disease (VAERD). RSV-A neutralizing titers and RSV F-binding antibody concentrations were higher post-ChAd155-RSV than postcomparator at days 31, 61, and end of RSV season 1 (mean follow-up, 7 months). High-dose ChAd155-RSV induced stronger responses than low-dose, with further increases post-dose 2.

Conclusions: ChAd155-RSV administered to 6- to 7-month-olds had a reactogenicity/safety profile like other childhood vaccines, showed no evidence of VAERD, and induced a humoral immune response. Clinical Trials Registration. NCT03636906.

Citing Articles

Immune Responses to Respiratory Syncytial Virus Vaccines: Advances and Challenges.

Silva G, Borges S, Pozzebon B, Souza A Microorganisms. 2024; 12(11).

PMID: 39597694 PMC: 11596275. DOI: 10.3390/microorganisms12112305.

Whole-Genome Sequencing and Genetic Diversity of Human Respiratory Syncytial Virus in Patients with Influenza-like Illness in Sicily (Italy) from 2017 to 2023.

Tramuto F, Maida C, Randazzo G, Guzzetta V, Santino A, Li Muli R Viruses. 2024; 16(6).

PMID: 38932144 PMC: 11209242. DOI: 10.3390/v16060851.

Vaccination for Respiratory Syncytial Virus: A Narrative Review and Primer for Clinicians.

See K Vaccines (Basel). 2023; 11(12).

PMID: 38140213 PMC: 10747850. DOI: 10.3390/vaccines11121809.

References

Jain S, Williams D, Arnold S, Ampofo K, Bramley A, Reed C . Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015; 372(9):835-45. PMC: 4697461. DOI: 10.1056/NEJMoa1405870. View

Bigay J, Le Grand R, Martinon F, Maisonnasse P . Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development. Front Microbiol. 2022; 13:932408. PMC: 9399815. DOI: 10.3389/fmicb.2022.932408. View

Rando H, Lordan R, Kolla L, Sell E, Lee A, Wellhausen N . The Coming of Age of Nucleic Acid Vaccines during COVID-19. mSystems. 2023; 8(2):e0092822. PMC: 10134841. DOI: 10.1128/msystems.00928-22. View

Schwarz T, Johnson C, Grigat C, Apter D, Csonka P, Lindblad N . Three Dose Levels of a Maternal Respiratory Syncytial Virus Vaccine Candidate Are Well Tolerated and Immunogenic in a Randomized Trial in Nonpregnant Women. J Infect Dis. 2021; 225(12):2067-2076. PMC: 9200160. DOI: 10.1093/infdis/jiab317. View

Liu X, Shaw R, Stuart A, Greenland M, Aley P, Andrews N . Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet. 2021; 398(10303):856-869. PMC: 8346248. DOI: 10.1016/S0140-6736(21)01694-9. View

Schmidt T, Klemis V, Schub D, Mihm J, Hielscher F, Marx S . Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med. 2021; 27(9):1530-1535. PMC: 8440177. DOI: 10.1038/s41591-021-01464-w. View

Simoes E, Center K, Tita A, Swanson K, Radley D, Houghton J . Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy. N Engl J Med. 2022; 386(17):1615-1626. DOI: 10.1056/NEJMoa2106062. View

Di Mattia G, Nenna R, Mancino E, Rizzo V, Pierangeli A, Villani A . During the COVID-19 pandemic where has respiratory syncytial virus gone?. Pediatr Pulmonol. 2021; 56(10):3106-3109. PMC: 8441855. DOI: 10.1002/ppul.25582. View

Wang W, Sayedahmed E, Mittal S . Significance of Preexisting Vector Immunity and Activation of Innate Responses for Adenoviral Vector-Based Therapy. Viruses. 2022; 14(12). PMC: 9787786. DOI: 10.3390/v14122727. View

10.

van Summeren J, Meijer A, Aspelund G, Casalegno J, Erna G, Hoang U . Low levels of respiratory syncytial virus activity in Europe during the 2020/21 season: what can we expect in the coming summer and autumn/winter?. Euro Surveill. 2021; 26(29). PMC: 8299745. DOI: 10.2807/1560-7917.ES.2021.26.29.2100639. View

11.

Tang J, Bialasiewicz S, Dwyer D, Dilcher M, Tellier R, Taylor J . Where have all the viruses gone? Disappearance of seasonal respiratory viruses during the COVID-19 pandemic. J Med Virol. 2021; 93(7):4099-4101. PMC: 8250511. DOI: 10.1002/jmv.26964. View

12.

Mendonca S, Lorincz R, Boucher P, Curiel D . Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. NPJ Vaccines. 2021; 6(1):97. PMC: 8342436. DOI: 10.1038/s41541-021-00356-x. View

13.

Benet T, Picot V, Messaoudi M, Chou M, Eap T, Wang J . Microorganisms Associated With Pneumonia in Children <5 Years of Age in Developing and Emerging Countries: The GABRIEL Pneumonia Multicenter, Prospective, Case-Control Study. Clin Infect Dis. 2017; 65(4):604-612. PMC: 7108107. DOI: 10.1093/cid/cix378. View

14.

Bardsley M, Morbey R, Hughes H, Beck C, Watson C, Zhao H . Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study. Lancet Infect Dis. 2022; 23(1):56-66. PMC: 9762748. DOI: 10.1016/S1473-3099(22)00525-4. View

15.

Cicconi P, Jones C, Sarkar E, Silva-Reyes L, Klenerman P, de Lara C . First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral.... Clin Infect Dis. 2019; 70(10):2073-2081. PMC: 7201425. DOI: 10.1093/cid/ciz653. View

16.

Hammitt L, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi S . Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med. 2022; 386(9):837-846. DOI: 10.1056/NEJMoa2110275. View

17.

Modjarrad K, Giersing B, Kaslow D, Smith P, Moorthy V . WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23-24 March 2015. Vaccine. 2015; 34(2):190-197. PMC: 6858870. DOI: 10.1016/j.vaccine.2015.05.093. View

18.

Atmar R, Lyke K, Deming M, Jackson L, Branche A, El Sahly H . Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl J Med. 2022; 386(11):1046-1057. PMC: 8820244. DOI: 10.1056/NEJMoa2116414. View

19.

Kampmann B, Madhi S, Munjal I, Simoes E, Pahud B, Llapur C . Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023; 388(16):1451-1464. DOI: 10.1056/NEJMoa2216480. View

20.

Anderson R, Huang Y, Langley J . Prospects for defined epitope vaccines for respiratory syncytial virus. Future Microbiol. 2010; 5(4):585-602. DOI: 10.2217/fmb.10.22. View